Astellas Pharma (OTCMKTS:ALPMY) Sees Strong Trading Volume – Here’s What Happened

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw an uptick in trading volume on Friday . 294,592 shares were traded during trading, an increase of 116% from the previous session’s volume of 136,389 shares.The stock last traded at $16.44 and had previously closed at $16.09.

Analyst Ratings Changes

Several equities research analysts have issued reports on ALPMY shares. Smbc Nikko Sec. upgraded Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. Citigroup cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Four research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23. The company’s fifty day moving average is $14.61 and its 200 day moving average is $12.61. The company has a market cap of $29.77 billion, a P/E ratio of 13.82 and a beta of 0.18.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.15. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. The business had revenue of $3.67 billion during the quarter, compared to the consensus estimate of $3.21 billion. As a group, equities analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).